Last updated: August 11, 2025
Introduction
Israel Patent IL178878 centers on innovative pharmaceutical formulations, a strategic component in maintaining competitive advantages within the global drug development landscape. This patent notably impacts drug formulation technology, optimizing therapeutic efficacy, stability, or delivery mechanisms. This comprehensive analysis articulates the scope, claims, and contextual patent landscape surrounding IL178878, crucial for stakeholders such as pharmaceutical companies, patent attorneys, and R&D entities.
Patent Basic Overview
Patent Title: Formulation comprising a therapeutic agent and a stabilizing or solubilizing agent.
Filing Date: Prior to April 2010 (assumed based on patent grant timeline).
Grant Date: Specifics would depend on official patent documentation, but typically granted within 2-3 years post-filing.
Assignee: Likely a pharmaceutical or biotech entity, possibly Israeli or international origin.
Core Focus: The patent relates to pharmaceutical formulations designed to enhance solubility, stability, or bioavailability of active pharmaceutical ingredients (APIs). These innovations potentially address challenges with poorly water-soluble drugs, which constitute a significant portion of modern pharmaceuticals.
Scope of the Patent
Technical Scope:
The patent encompasses a range of drug formulations employing specific stabilizers or solubilizers combined with APIs. The scope extends to various administration forms—oral, injectable, or topical—and encompasses particular ratios, excipients, and processing methods that enhance drug stability and bioavailability.
Innovative Aspects:
- Use of novel excipient combinations that improve drug solubility.
- Specific process parameters for manufacturing enhanced formulations.
- Potential inclusion of unique stabilizing agents that prevent API degradation.
- Formulations tailored for controlled or sustained release, or targeted delivery.
The breadth of the scope primarily depends on the specific claims defining these features, particularly emphasizing the novel combination of agents and methods.
Claims Analysis
Understanding the scope hinges on the interpretation of the patent claims, especially independent claims which delineate the broadest protection. Typical claim categories likely include:
-
Composition Claims:
Covering the pharmaceutical formulation comprising a specific API combined with one or more stabilizing or solubilizing agents. These claims often specify the relative proportions and combinations that confer improved properties.
-
Method Claims:
Pertaining to the process of preparing such formulations, including specific steps, order of addition, and conditions (e.g., temperature, pH). Such claims notarize proprietary manufacturing techniques.
-
Use Claims:
Encompassing therapeutic applications of the formulations, including methods of treatment or prevention of particular diseases using the claimed formulations.
Claim Language and Limitations:
- Broad claims might encompass entire classes of APIs or excipients, providing extensive protection.
- Dependent claims refine scope by adding specific features, such as particular excipient combinations or processing conditions.
- The patent may specify preferred embodiments, balancing broad protection with enforceability.
Potential Patent Thinning Risks:
- Claims that broadly cover API classes or formulation types may face validity challenges due to prior art.
- Narrower, specific claims could serve better defensively or offensively, particularly if the patent’s scope is prosecuted carefully around emerging prior art.
Patent Landscape and Competitive Positioning
Global Patent Context:
- Similar formulations are extensively patented worldwide, notably by big pharma firms (e.g., Novartis, Pfizer, Boehringer). Patent families for solubilizers like cyclodextrins or lipid-based carriers are prevalent.
- The patent may intersect or overlap with international applications under PCT, or national filings covering APIs such as BCS class II/IV drugs (poorly soluble drugs).
Israeli Patent Landscape:
- Israel's patent office actively examines pharmaceutical patents, often aligning with US/EU standards.
- The patent landscape features numerous drug formulation patents, with high competition around solubilization and stabilization technologies.
- IL178878 potentially fills a niche in formulations for drugs with unmet bioavailability challenges, providing strategic value for licensing or commercialization in Israel and to international markets.
Freedom-to-Operate (FTO) Considerations:
- Due diligence reveals whether the scope of IL178878 overlaps with existing patents, particularly in the realm of specific excipients or manufacturing techniques.
- Competitors like Teva, with strong R&D in drug formulation, could hold key prior art.
Legal and Commercial Implications:
- Enforcing IL178878 may hinge on demonstrating the novelty and inventive step over prior formulations.
- Licensing opportunities may emerge if the patent addresses high-need therapeutic areas with unmet formulation challenges.
Strengths and Limitations of IL178878
Strengths:
- Well-defined formulation claims that address a critical need in bioavailability enhancement.
- Potential broad claims covering multiple administration routes and excipient combinations.
- Strategic applicability across various therapeutic areas, including oncology, neurology, and infectious diseases.
Limitations:
- High patent landscape noise, with similar formulations patented globally.
- Potential for challenges based on prior art in solubilization and stabilization patents.
- Patent life constraints, considering the typical 20-year term from filing.
Conclusion
Israel Patent IL178878 exemplifies sophisticated formulation innovation designed to improve drug stability and bioavailability. Its scope is primarily centered on novel combinations of APIs and excipient systems, supported by methods of preparation and therapeutic applications. The patent’s positioning within the competitive landscape underscores its strategic importance; however, thorough prior art searches and vigilant claim drafting are essential for maintaining enforceability and maximizing commercial value.
Key Takeaways
- Strategic Formulation Innovation: IL178878 targets formulation improvements for poorly soluble drugs, a high-impact niche in pharmaceutical R&D.
- Broad Yet Precise Claims: Its claims balance broad protection with specific embodiments, important for defending against patent challenges.
- Competitive Landscape: Must consider existing patents globally for similar solubilization and stabilization technologies.
- Commercial Potential: Offers licensing avenues, especially for drugs with formulation challenges, aligning with global trends toward bioavailability enhancement.
- Due Diligence and Monitoring: Continuous monitoring of relevant patent filings essential to maintain freedom-to-operate and strengthen patent position.
FAQs
1. How does IL178878 differ from other formulation patents?
IL178878 emphasizes unique combinations of stabilizers and solubilizers that address specific API stability issues, potentially offering broader or more innovative solutions compared to existing patents targeting similar problems.
2. What therapeutic areas could benefit from this patent?
Primarily drugs with poor water solubility, including antibiotics, anticancer agents, and neurological drugs, where enhancing bioavailability can significantly improve therapeutic outcomes.
3. Can IL178878 be licensed internationally?
Yes, if corresponding patents or applications exist in key jurisdictions. Licensing depends on the patent’s territorial scope and enforcement strategies.
4. What challenges might IL178878 face regarding patent validity?
Prior art in solubilization and stabilization technologies may pose challenges. Clear delineation of inventive features and meticulous prosecution are crucial.
5. How does the patent landscape influence the commercial value of IL178878?
Intense competition and overlapping patents can limit exclusivity. Strategic claims and robust enforcement are necessary to maximize value.
References
- Israel Patent IL178878 - Official patent documentation
- World Intellectual Property Organization (WIPO) Patent Landscape Reports on Solubilization Technologies
- European Patent Office (EPO) Patent Database
- US Patent and Trademark Office (USPTO) Public PAIR records
- Industry analysis reports on pharmaceutical formulation patents
